Clinical trials: Gut Biome
DLBCL, Glofitamab
Gut Microbiome in DLBCL Treated With Glofitamab
The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients.
- Conditions
- DLBCL, Glofitamab, Gut Biome
- Trial name
- NCT07498920
- Testing
- Gut microbiome analysis
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Alzheimer Disease, Gut Biome
Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers
Spousal caregivers of Alzheimer's Dementia (AD) patients have an elevated risk of developing AD in the future. Past studies have shown the presence of serum indicators correlated with gut biome dysfunction in AD patients.
- Trial name
- NCT05601856
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of Virginia